Navigation Links
UCI researchers find new way to fight cocaine addiction

Irvine, Calif., April 1, 2009 UC Irvine pharmacological researchers have discovered that blocking a hormone related to hunger regulation can limit cocaine cravings. Their findings could herald a new approach to overcoming addiction.

Led by Shinjae Chung and Olivier Civelli, the study identified how the melanin-concentrating hormone works with dopamine in the brain's "pleasure center" to create an addictive response to cocaine use. The researchers further found that blocking MCH in these brain cells limited cocaine cravings.

Dopamine is a neurotransmitter essential to the normal functioning of the central nervous system. It also is associated with feelings of pleasure and is released in the brain during eating, sex and drug use. Heightened levels of the neurotransmitter have been detected in the nucleus accumbens of drug addicts.

The study is the first to detail the interaction of MCH and dopamine in cocaine addiction and show that it occurs in the nucleus accumbens, a portion of the forebrain believed to play an important role in addiction and feelings of pleasure and fear. Study results appear in this week's early online edition of the Proceedings of the National Academy of Sciences.

"This discovery indicates that MCH is a key regulator of dopamine in a brain area associated with both pleasure and addiction," says Civelli, the Eric L. and Lila D. Nelson Professor of Neuropharmacology. "We believe that efforts to target MCH may lead to new treatments to break addiction to cocaine and, possibly, other drugs, like amphetamines and nicotine."

In mammals, MCH is involved with the regulation of feeding behavior and energy balance. High levels of the hormone can intensify feelings of hunger, and researchers worldwide have been seeking compounds to lower MCH for potential use in the treatment of obesity.

Chung and Civelli believe MCH works in the nucleus accumbens to increase the pleasure of eating. They found that dopamine signaling rose when MCH amounts increased in those brain cells.

The UCI researchers found that test mice conditioned to develop cocaine cravings had increased amounts of MCH and dopamine in their nucleus accumbens. When experimental compounds blocking MCH proteins were administered, those cravings disappeared. In addition, Chung and Civelli discovered that mice lacking key receptors for MCH exhibited significantly fewer cocaine cravings.

They hope to learn whether modulating MCH might be beneficial in treating other dopamine-related disorders as well.


Contact: Tom Vasich
University of California - Irvine

Related medicine news :

1. Researchers question effectiveness of warning labels on over-the-counter drugs
2. Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas
3. Yale researchers discover mechanism for
4. Three Johns Hopkins researchers named Howard Hughes Medical Institute early career scientists
5. Researchers decipher blood stem cell attachment, communication
6. Researchers studying hearing loss find auditory regions of the brain convert to the sense of touch
7. UIC researchers measure health effects of Chicagos waterways
8. Focus on treating malnutrition in cancer patients, researchers say
9. Researchers Suspect Genetic Link to COPD
10. Syracuse University researchers build a new surface material that resists biofilm growth
11. Researchers Use Gene to End High Blood Sugar in Mice
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: